|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
18.940 +0.710 (+3.895%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 41,498,325 | 1.438% | 40,909,878 | 41,248,505 | 43,811,385 | 38,864,174 |
| Cost of Sales | (20,800,103) | -2.647% | (21,365,574) | (21,595,309) | (23,169,690) | (20,229,785) |
| Gross Profit | 20,698,222 | 5.904% | 19,544,304 | 19,653,196 | 20,641,695 | 18,634,389 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (125,175) | 13.146% | (110,631) | (131,927) | (65,369) | (74,016) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 1,923,979 | 17.042% | 1,643,839 | 2,184,849 | 1,835,146 | 1,789,137 | |
| Profit / (Loss) before Taxation | 5,111,984 | 22.611% | 4,169,281 | 3,276,908 | 4,580,552 | 6,042,670 | |
| Taxation | (864,054) | 31.547% | (656,841) | (369,504) | (626,918) | (1,066,401) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (877,368) | 18.155% | (742,554) | (508,798) | (216,659) | (247,558) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,370,562 | 21.686% | 2,769,886 | 2,398,606 | 3,736,975 | 4,728,711 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 964,847 | -8.865% | 1,058,705 | 961,186 | 681,172 | 588,755 |
| Depreciation & Amortisation | 3,847,990 | 18.687% | 3,242,146 | 3,202,753 | 2,496,331 | 1,948,448 |
| Directors' Emoluments | -- | -- | 21,284 | 48,086 | 50,007 | 39,627 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 127.000 | 22.115% | 104.000 | 90.000 | 143.000 | 185.000 |
| DPS (cts) | 39.000 | -- | 32.000 | 27.000 | 42.000 | 56.000 |
| Dividend Payout Ratio (%) | 30.709% | -- | 30.769% | 30.000% | 29.371% | 30.270% |
| Cash flow per share ($) | -- | -- | 1.677 | 1.279 | 1.618 | 1.536 |
| NBV per share ($) | 18.451 | -- | 17.766 | 17.081 | 16.665 | 15.271 |
| Remarks: | Real time quote last updated: 25/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,370,562 |
| %Change | 21.686% |
| EPS / (LPS) | RMB 1.270 |
| NBV Per Share (¥) | RMB 18.451 |